Converge Bio, the AI platform for accelerated drug discovery and development, announced today $25 million in Series A funding, bringing its total raised to $30 million. The round was led by Bessemer ...
Accelerated drug discovery and development platform Converge Bio Inc. today announced it has raised $25 million in ...
AI drug discovery startup Converge Bio raised $25 million in a Series A led by Bessemer Venture Partners, with additional ...
Lilly and NVIDIA launch AI co-innovation lab to tackle drug discovery challenges.NVIDIA collaborates with Thermo Fisher to ...
In 2023, North America dominated the the global AI in drug discovery market and is poised to maintain this leadership during ...
The U.S. Food and Drug Administration and the European Medicines Agency jointly issued principles for safe and responsible ...
MIT researchers are now turning the prolific Boltz series of models into a software company that promotes open science for AI-guided therapeutics.
M&G Investments (M&G) today announces that it has led a US$50 million Series C funding round for bit.bio, the Cambridge-based biotech company pioneering next-generation human cell programming ...
In this interview, Dr. Malika Bsibsi discusses the role of iPSC models in advancing neuroscience drug discovery, focusing on neurodegeneration, neuroinflammation, and innovative in vitro ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback